(NASDAQ: VKTX) Viking Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.98%.
Viking Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VKTX's revenue for 2025 to be $2,811,124,025, with the lowest VKTX revenue forecast at $2,811,124,025, and the highest VKTX revenue forecast at $2,811,124,025. On average, 1 Wall Street analysts forecast VKTX's revenue for 2026 to be $1,124,449,610, with the lowest VKTX revenue forecast at $1,124,449,610, and the highest VKTX revenue forecast at $1,124,449,610.
In 2027, VKTX is forecast to generate $333,961,534 in revenue, with the lowest revenue forecast at $333,961,534 and the highest revenue forecast at $333,961,534.